BIOMEDICA MANAGEMENT CORP.

Address

760 Parkside Ave., #304
BROOKLYN, NY, -

Information

DUNS: 146587345
# of Employees: 7

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Clinical Development of Hemostatic Agent ClotFoam for Severe Hemorrhage

    Amount: $1,977,696.00

    DESCRIPTION (provided by applicant): ClotFoam(R) , is a novel adhesive sealant composition and second-generation hemostatic agent. This biological agent was designed to arrest moderate to severe bl ...

    SBIRPhase II2012Department of Health and Human Services
  2. Clinical Development of Non-compressible Hemostatic Agent for High-Volume Hemorrhage

    Amount: $1,982,696.00

    DESCRIPTION provided by applicant andquot ClotFoam R andquot is a novel adhesive sealant composition and second generation hemostatic agent This biological agent was designed to arrest moderate ...

    SBIRPhase II2012Department of Health and Human Services
  3. Intracavitary Hemostatic Agent for Non-compressible Hemorrhage

    Amount: $1,001,010.00

    DESCRIPTION (provided by applicant): Hemorrhage resulting from traumatic injuries is a major cause of death in accidents, and the primary cause of death on the battlefield. Over 40% of the trauma case ...

    SBIRPhase II2009Department of Health and Human Services
  4. non-compressible Biodegradable Hemostatic Agent

    Amount: $69,998.00

    we propose to determine the biocompatibility of ClotFoam and enhance its hemostastic and non-compressible sealing effects against a severe parenchymial hemorrhage caused by a wound grade V affecting m ...

    SBIRPhase I2009Army Department of Defense
  5. Tissue Sealant for Intracavitary Non-compressible Hemorrhage

    Amount: $98,957.00

    ClotFoam is a novel crosslinked polymer designed to stop hemorrhage without compression in severe wounds outside the operating room. ClotFoam’s ability to promote hemostasis in cases severe bleeding ...

    SBIRPhase I2008Defense Advanced Research Projects Agency Department of Defense
  6. Immunomodulation of Sophorolipids in Sepsis

    Amount: $99,999.00

    DESCRIPTION (provided by applicant): Microbial sophrolipids are a new a class of membrane-derived glycolipids that have wide ranging potential in clinical practice. We have demonstrated that sophoroli ...

    SBIRPhase I2008Department of Health and Human Services
  7. Anti-ischemic Resuscitation Fluid

    Amount: $104,178.00

    DESCRIPTION (provided by applicant): Inflammation after ischemia and reperfusion (I/R) injury secondary to hemorrhagic shock is responsible for significant mortality and morbidity in the United States ...

    SBIRPhase I2007Department of Health and Human Services
  8. Intracavitary Hemostatic Agent for Non-compressible Hemorrhage

    Amount: $103,148.00

    DESCRIPTION (provided by applicant): Hemorrhage resulting from traumatic injuries is a major cause of death in accidents, and the primary cause of death on the battlefield. Early and effective hemorrh ...

    SBIRPhase I2007Department of Health and Human Services
  9. Anti-Selectin Blocker for Liver Ischemic Injury

    Amount: $719,044.00

    DESCRIPTION (provided by applicant): Our objective is to develop a new treatment that will prevent or decrease the tissue damage caused by neutrophil infiltration after ischemia/reperfusion (I/R), ...

    SBIRPhase II2004Department of Health and Human Services
  10. ANTI-SELECTIN BLOCKER FOR ORGAN ISCHEMIC INJURY

    Amount: $107,000.00

    Description (provided by applicant): Drugs currently available for the treatment of ischemic (lack of blood supply) conditions are not satisfactory. Since selectins have a primordial role in the devel ...

    SBIRPhase I2002Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government